Journal of Parkinson's disease最新文献

{"title":"<i>Lactobacillaceae</i> and Parkinson's disease: An apparent paradox.","authors":"Marieke Me van der Maden, Marcel M Verbeek, Milan Beckers","doi":"10.1177/1877718X241312401","DOIUrl":"10.1177/1877718X241312401","url":null,"abstract":"<p><p>Parkinson's disease (PD) is a neurodegenerative disorder predominantly known for its motor symptoms such as bradykinesia, rigidity and tremor, but the disorder is also increasingly recognized for its association with impaired gastrointestinal function. The composition of the gut microbiome is known to be different in PD compared with healthy individuals. One of the bacterial families with increased abundance in people with PD is <i>Lactobacillaceae</i>. Interestingly, opposite effects have been ascribed to <i>Lactobacillaceae</i> in PD. A number of studies have linked <i>Lactobacillaceae</i> spp. in the gut to worse motor function, and to premature degradation of levodopa. However, other studies have linked administration of <i>Lactobacillaceae</i>-containing probiotics to improved motor function and reduced gastrointestinal problems. In this narrative review, we investigate this apparent paradox. The key to its understanding appears to lie in the specific species of <i>Lactobacillaceae</i>. The species <i>L. plantarum</i> in particular seemed to show a correlation with improved motor symptoms, as well as a reduction in intestinal inflammation, whereas <i>L. brevis, L. curvatus</i> and <i>L. fermentum</i> have properties that might be detrimental to people with PD.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"269-281"},"PeriodicalIF":4.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Saccade, pupil, and blink abnormalities in prodromal and manifest alpha-synucleinopathies.","authors":"Maha Habibi, Brian C Coe, Donald C Brien, Jeff Huang, Heidi C Riek, Frank Bremmer, Lars Timmermann, Annette Janzen, Wolfgang H Oertel, Douglas P Munoz","doi":"10.1177/1877718X241308193","DOIUrl":"10.1177/1877718X241308193","url":null,"abstract":"<p><p>BackgroundSaccade, pupil, and blink control are impaired in patients with α-synucleinopathies (αSYN): Parkinson's disease (PD) and multiple system atrophy (MSA). Isolated REM (rapid eye movement) Sleep Behavior Disorder (iRBD) is a prodromal stage of PD and MSA and a prime candidate for investigating early oculo-pupillo-motor abnormalities that may precede or predict conversion to clinically manifest αSYN.ObjectiveDetermine whether saccade, pupil, and blink responses in iRBD are normal or similar to those identified in PD and MSA.MethodsVideo-based eye-tracking was conducted with 68 patients with iRBD, 49 with PD, 17 with MSA, and 95 healthy controls (CTRL) performing an interleaved pro-/anti-saccade task that probed sensory, motor, and cognitive processes involved in eye movement control.ResultsHorizontal saccade and blink behavior was intact in iRBD, but abnormal in PD and MSA. iRBD patients, however, demonstrated reduced pupil dilation size, which closely resembled the changes found in PD and MSA. In the iRBD group, the extent of these pupillary changes appeared to correlate with the degree of hyposmia and reduction in dopamine transporter imaging signal.ConclusionsPupil abnormalities were present in iRBD, but blink and horizontal saccade responses were intact. Future longitudinal studies are required to determine which prodromal pupil abnormalities predict conversion from iRBD to PD or MSA and to identify the time window, in relation to conversion, when horizontal saccade responses become abnormal.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"300-310"},"PeriodicalIF":4.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of 6 months of endurance exercise on motor function, exercise capacity, and autonomic function based on presence of autonomic dysfunction in individuals with early Parkinson's disease.","authors":"Garett J Griffith, Niyati Mehta, Guillaume Lamotte, Kathleen E McKee, Erin Suttman, Jacob M Haus, Elizabeth Joslin, Katherine Balfany, Wendy M Kohrt, Cory L Christiansen, Edward L Melanson, Lana M Chahine, Demetra D Christou, Charity G Patterson, Daniel M Corcos","doi":"10.1177/1877718X241308813","DOIUrl":"10.1177/1877718X241308813","url":null,"abstract":"<p><p>BackgroundEndurance exercise improves aerobic capacity (VO_2peak) and motor symptoms in people with early Parkinson's disease (PD). Some people with PD exhibit signs of chronotropic incompetence (CI), which may impact exercise-induced benefits.ObjectiveWe investigated whether CI in people with early PD influences the change in motor signs, VO_2peak, and peak heart rate (HR) following 6 months of endurance exercise.MethodsWe performed secondary analyses of the Study in Parkinson's Disease of Exercise (SPARX), which randomized people with early PD into a high-intensity endurance exercise [80-85% of peak HR], moderate-intensity endurance exercise [60-65% of peak HR], or usual care group. MDS-UDPRS Part 3 score, VO_2peak, and heart rate (HR) response to maximal cardiopulmonary exercise testing (CPET) were analyzed at baseline and following 6 months of exercise. Participants were divided into three groups: 1) normal chronotropic response at baseline, 2) CI at baseline, and 3) taking medications with a known negative chronotropic effect regardless of CI status.ResultsData from 119 individuals (64.0 ± 9.0 years, 57.1% male, 0.3 years since diagnosis [median]) were analyzed. There were no differences among the groups in change in MDS-UPDRS motor score (<i>p </i>= 0.953), VO_2peak (<i>p </i>= 0.965), or peak HR (<i>p </i>= 0.388). People randomized into the high-intensity group improved VO_2peak compared to usual care (<i>p </i>< 0.001_adj) regardless of CI status.ConclusionsBaseline CI did not alter responses to endurance exercise in those with early PD, suggesting that the beneficial effects of endurance exercise on disease progression and VO_2peak in people with early PD apply equally to people with CI.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"387-396"},"PeriodicalIF":4.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two-year feasibility and safety of open-label autologous peripheral nerve tissue implantation during deep brain stimulation in patients with Parkinson's disease.","authors":"Jorge E Quintero, Monica J Chau, John T Slevin, Lisa Koehl, Julie A Gurwell, Elizabeth Wallace, Richard J Kryscio, Riham El Khouli, Amelia J Anderson-Mooney, Frederick A Schmitt, Greg A Gerhardt, Craig G van Horne","doi":"10.1177/1877718X241312409","DOIUrl":"10.1177/1877718X241312409","url":null,"abstract":"<p><p>BackgroundMotor dysfunction in Parkinson's disease (PD) is characterized by a loss of functioning neurons in the substantia nigra. Two options exist when encountering damaged neurons: replace or support. We implemented a strategy of using autologous peripheral nerve tissue, in a reparative state, to provide a collection of neurorestorative support to unhealthy neurons with the goal of modifying the motor progression of PD.ObjectiveReport on two-year compliance feasibility, safety, and clinical experience of combining this delivery at the time of deep brain stimulation (DBS) surgery.MethodsParticipants with PD undergoing open-label peripheral nerve tissue implantation to the substantia nigra at the time of DBS surgery were followed from pre-surgery to two years after surgery through clinical evaluations.ResultsSeventeen of 18 participants who underwent the procedure completed the 2-year study visits. No study-related serious adverse events occurred.ConclusionsThe trial met its primary endpoints of feasibility and safety. We were able to practicably and safely implant participants and have participants comply with 2-year visits and exams. Adverse events related to study participation were deemed manageable by participants.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"397-408"},"PeriodicalIF":4.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143501848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A perspective of persons with Parkinson's disease on the contribution of alpha-synuclein seed amplification assay biomarker to the diagnosis of Parkinson's disease.","authors":"Susanne Bowen, David Blacker, Richard Prettyman","doi":"10.1177/1877718X251315651","DOIUrl":"https://doi.org/10.1177/1877718X251315651","url":null,"abstract":"<p><p>Alpha-synuclein is a normal protein, but misfolded forms in the cerebrospinal fluid can be detected using the alpha-synuclein seed amplification assay (αSyn-SAA), a potential biomarker for Parkinson's disease (PD). Some experts consider this assay a 'game changer' for redefining and reclassifying PD. In this article, we, three individuals with PD, share our perspective on the suitability of αSyn-SAA as the basis for a new classification and staging system for PD. We also discuss other biomarkers and their relevance to those with PD, drawing on our research and the scientific background of two authors. We aim to clarify complex media reports and study findings for the PD community. We argue that while αSyn-SAA can identify the presence of pathology, it cannot explain the underlying cause for such pathology or predict the progression of PD. Given the varied biological pathways leading to PD, using αSyn-SAA as a unified biological definition for a new classification system is premature. Further research is needed before it can serve as the foundation for defining and staging Parkinson's disease. Although αSyn-SAA has its place, like the DAT scan, it should be seen as a tool for confirming diagnoses rather than defining them.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X251315651"},"PeriodicalIF":4.0,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological definitions of synucleinopathies should be anchored in clinical trajectories and encompass the complex biology of the disease.","authors":"David Bendetowicz, Vincent Planche, Erwan Bezard, Benjamin Dehay, Wassilios G Meissner","doi":"10.1177/1877718X241313443","DOIUrl":"https://doi.org/10.1177/1877718X241313443","url":null,"abstract":"<p><p>Recently, two proposals for defining Parkinson's disease and its related pathogenic processes have been published. In this viewpoint, we discuss the primary drivers behind these efforts, the future directions, and the challenges that must be addressed. While finding biomarkers is a mandatory step for better precision medicine and optimal patient stratification in therapeutic trials, we argue that a biological definition of Parkinson's disease based on a single biomarker will struggle to account for the complexity of the mechanisms involved in developing the disease. Additionally, a biological definition of asymptomatic patients should rely on a thorough understanding of patients' clinical trajectories, which is currently not the case in synucleinopathies.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X241313443"},"PeriodicalIF":4.0,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to advance the pharmacological management of cognitive impairment in Parkinson's disease.","authors":"Carla Abdelnour, Lucy L Gibson, Lucia Batzu, Dag Aarsland","doi":"10.1177/1877718X251315645","DOIUrl":"https://doi.org/10.1177/1877718X251315645","url":null,"abstract":"<p><p>Cognitive impairment is a common non-motor symptom in people with Parkinson's disease (PD) and is associated to poor clinical outcomes. Currently, rivastigmine is the only approved medication for PD dementia, and there are no treatments available for people with PD and mild cognitive impairment. To advance the pharmacological management of cognitive impairment in PD, it is essential to optimize clinical trial design. This includes refining cognitive outcome measures, ensuring longer study durations, and incorporating PD-specific cognitive assessments. Biomarkers offer valuable opportunities for screening, stratification, enrichment, and monitoring in trials, increasing the likelihood of detecting treatment effects. Additionally, adopting patient-centered approaches that prioritize inclusivity can enhance trial validity and address the current lack of diversity in PD studies. Digital cognitive assessments offer a promising tool for improving participation and enabling longitudinal monitoring, especially in underrepresented and mobility-challenged populations. By tackling these challenges, this review outlines strategies for advancing the pharmacological management of cognitive impairment in PD. It emphasizes the need for precise, inclusive, and biomarker-driven trials to accelerate drug development.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X251315645"},"PeriodicalIF":4.0,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Technology for measuring freezing of gait: Current state of the art and recommendations.","authors":"Martina Mancini, J Lucas McKay, Helena Cockx, Nicholas D'Cruz, Christine D Esper, Benjamin Filtjens, Benedetta Heimler, Colum D MacKinnon, Luca Palmerini, Melvyn Roerdink, William R Young, Jeffrey M Hausdorff","doi":"10.1177/1877718X241301065","DOIUrl":"10.1177/1877718X241301065","url":null,"abstract":"<p><p>This report summarizes the existing literature on the use of technology for the assessment of freezing of gait (FOG) as well as the use of technology to provide insights into the mechanisms of FOG in people with Parkinson's disease. Specifically, this work was carried out for the 3rd International Workshop on Freezing of Gait in Jerusalem in 2023. This review focuses on the most used technologies to quantitatively assess FOG in a laboratory environment and describes the technologies that hold promise for assessing FOG in daily life. Examples of implementation of machine learning algorithms are provided as well as algorithmic biases. Lastly, a standardized assessment using inertial measurement units during a clinical protocol is proposed and a 5-year outlook is discussed. We anticipate this review will help move the field forward in the coming years.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"19-40"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing the need for standardization of symptomatic medication documentation in Parkinson's disease clinical research: A call to action.","authors":"Mikayla Spott, Monica Javidnia, Anne Pedata, Martijn Müller, Laura Carrillo, Tanya Simuni, Gennaro Pagano, Kevin Kwok, Klaus Romero, Diane Stephenson","doi":"10.1177/1877718X241305711","DOIUrl":"10.1177/1877718X241305711","url":null,"abstract":"<p><p>People with Parkinson's disease (PD) are prescribed a variety of medications to mitigate symptoms and improve their quality of life. These symptomatic therapies cover a range of pharmacological classes, including classical dopaminergic treatments, other antiparkinsonian agents, and pharmacotherapies for non-PD conditions. Often, medications are prescribed for concomitant use and in increasing doses, particularly as the disease progresses. Documentation of these interventions in clinical trials is necessary to accurately capture medication usage, compare medication utilization across different studies, understand factors contributing to experimental therapeutic response, and analyze clinical trial data in a precise manner. At the present time, there is no current international standard for how these medications are documented within clinical trials. As a case example, we will highlight medication use documentation in a large international multicenter observational study commonly used as a reference for design of clinical trials. This review aims to raise awareness within the scientific community of the importance of proper medication documentation and the need for standardization to harmonize prescriptive practices, improve treatment interpretability, and perform consistently robust analyses from clinical trials data.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"227-235"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subcortical tau burden correlates with regional brain atrophy and plasma markers in four-repeat tauopathy parkinsonism.","authors":"Cheng-Hsuan Li, Sung-Pin Fan, Ming-Chieh Shih, Yi-Hsin Weng, Ta-Fu Chen, Hsun Li, Mei-Fang Cheng, Ming-Che Kuo, Pei-Ling Peng, Makoto Higuchi, Ing-Tsung Hsiao, Kun-Ju Lin, Chin-Hsien Lin","doi":"10.1177/1877718X241298192","DOIUrl":"10.1177/1877718X241298192","url":null,"abstract":"<p><p>Background¹⁸F-florzolotau positron emission tomography (PET) assists in the <i>in vivo</i> diagnosis of progressive supranuclear palsy (PSP).ObjectiveWe aimed to investigate the relationship between ¹⁸F-florzolotau uptake and clinical severity, structural volume changes, and plasma markers in four-repeat tauopathies.MethodsA total of 80 participants were recruited: 35 with PSP (11 with PSP-Richardson syndrome and 24 with PSP non-Richardson syndrome), 9 with corticobasal syndrome (CBS), 10 with Alzheimer's disease (AD), 8 with Parkinson's disease, and 18 controls. All participants underwent ¹⁸F-florzolotau PET, brain magnetic resonance imaging (MRI), and plasma biomarker investigation (total and phosphorylated tau [pTau181], neurofilament light chain, and glial fibrillary acidic protein [GFAP]).Results¹⁸F-Florzolotau uptake was significantly higher in the subcortical regions of the pallidum, subthalamic nucleus (STN), midbrain, red nucleus, and raphe nucleus in PSP patients compared to the other groups (all <i>p </i>< 0.01). Subcortical tau tracer retention assisted in distinguishing PSP and CBS from controls (AUC = 0.836, <i>p </i>< 0.001). Tau tracer retention could differentiate PSP and CBS from AD in cortical (<i>p </i>< 0.001) and subcortical regions (<i>p </i>= 0.028). The motor severity of PSP positively correlated with tau burden in STN (<i>p </i>= 0.044) and substantia nigra (<i>p </i>= 0.035). Tau tracer uptake was associated with cortical volume changes in CBS (<i>p </i>= 0.031), PSP non-Richardson syndrome (<i>p </i>= 0.003), and AD (<i>p </i>= 0.044). Cortical tau retention correlated with plasma levels of GFAP (<i>p </i>= 0.001) and pTau181 (<i>p </i>= 0.036).ConclusionsSubcortical ¹⁸F-Florzolotau uptake assist the diagnosis of 4R tauopathy parkinsonism. Additionally, regional tau burden contributes to structural brain volume changes and correlates with plasma levels of GFAP and pTau181.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"214-226"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}